Investor Presentation

Ref: Syn/CS/SE/IP/2026-27/Jul/18 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 9191 CIN: L85110KA1993PLC014937 www.syngeneintl.com July 29, 2026 To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE Dear Sir/Madam, Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter ended June 30, 2026. The Company will use this presentation for any meeting scheduled with analysts or institutional investors. The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com. This is for your information and records. Thanking You, Yours faithfully, For SYNGENE INTERNATIONAL LIMITED Chethan Yogesh Company Secretary and Compliance Officer Enclosed: Investor Presentation. Investor Presentation July 2026 Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition. Putting Science to Work 2 Contents Q1 FY27 Highlights Syngene – Putting Science to Work Syngene strengths Financials Shareholding and Share Information Putting Science to Work 3 Q1 FY27 Highlights Q1 FY27 performance Operating Highlights Q1 FY27 Financial Highlights • Siddharth Mittal assumed charge as Managing Director & CEO on July 1, 2026 Revenue from Operations Rs 736 Cr ( -16% Y-o-Y) • Signed a Memorandum of Understanding (MoU) with BRIC-Translational Health Science and Technology Institute (THSTI), an institute under the Biotechnology Research Innovation Council Operating EBITDA margin 12% (24% in Q1 FY26) (BRIC), Department of Biotechnology, Ministry of Science and Technology, Government of India. The collaboration establishes a joint operational partnership for early and late-phase clinical development, translational research and bioanalytical sciences PAT, before exceptional items1 Rs. 1 Cr • Further strengthened Syn.AI, Syngene’s AI-enabled scientific platform for accelerating drug PAT, after exceptional items Rs -9 Cr discovery services. Syngene developed gigascale virtual screening capabilities, enabling larger libraries of molecules to be screened and prioritized, helping clients identify promising drug candidates faster. Syngene also advanced its AI-driven de novo (new molecule) design • Our performance during the quarter was primarily impacted by the lack of offtake capabilities, enabling faster design and optimization of novel drug candidates from a major LMCDMO client and forex hedge loss, partially offset by our ongoing cost optimization initiatives. • Featured in TIME Magazine and Statista's "World's Most Sustainable Companies 2026" ranking for the second consecutive year. Selected from more than 5,800 companies across 43 • While we expect a degrowth in the first half of the fiscal year, business momentum countries, Syngene was ranked among the world's top 750 most sustainable companies and is expected to improve in the second half, resulting in single-digit revenue continues to be recognized as one of the leading pharmaceutical and biotechnology companies degrowth in rupee terms for the full year and EBITDA margins in the mid-20s globally 1Excludes expenses of Rs 10 Cr (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy Putting Science to Work 5 Syngene – Putting Science to Work Partner in innovation: #Putting Science to Work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more than Established track record in solutions across pharmaceuticals, biotech, ~5,700+ scientists out of total discovery research and research, development nutrition, animal health, 8,300+ headcount, operating development/ and manufacturing consumer goods and across 4 global state-of-the-art manufacturing for small specialty chemicals campuses located in India’s and large molecules leading life science hubs: Bangalore, Mangalore, Hyderabad and USA (Baltimore) Putting Science to Work 7 Our journey so far 2019 – 2026 Globalization and strategic collaboration Continued investments and growth • Expanded into formulations development • Laboratory capacity expansion in Bangalore and Hyderabad • Contract with Endo Pharmaceuticals to develop novel anti cancer biological therapeutic molecules • Expansion in Mangalore for commercial API manufacturing • Extension of collaboration with BMS; • Capacity and capability addition in Biologics • Merger of Clinigene 2015 – manufacturing • Crossed annual turnover of Rs. 5 Billion 2018 • Entered in long-term partnership with Zoetis for Biologics commercial-scale manufacturing Foundation 2010 – • Acquired multi-modal biologics • Operations started IPO and further 2014 manufacturing facility from Stelis Biopharma • Expansion of R&D Lab collaborations • Granted 100% EOU status • IPO and listing • Acquired 17 acres land in Hyderabad to by the Government of India • Collaboration with support long term growth in research 2001 – Amgen to set up a business 2009 dedicated R&D center • Acquired, state of the art first biologics site Expansion in Baltimore, USA taking Syngene’s total • Expanded service offerings to single-use bioreactor capacity to 50,000L 1993 – include chemical • Invested in new capabilities and emerging 2000 development, safety modalities, such as peptides and ADCs, assessment, biologics ensuring alignment with growing global development demand • Collaboration with BMS to set up BBRC, Syngene’s first dedicated R&D Center Putting Science to Work 8 Key facts and figures ~400 16 out of top 20 400+ World class infrastructure active clients pharma companies are patents International presence with global clients held with clients campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards Rs. 3,739 Cr Rs. 380 Cr* 8,373 headcount 92% FY26 Revenue from FY26 PAT 5,778 energy from including operations renewable sources talented scientists All figures are as on March 31, 2026 / FY2026, unless otherwise specified *before exceptional items Putting Science to Work 9 Syngene – one of the largest integrated CRDMO players in India One-stop platform for integrated drug di [Showing first 8,000 characters — download PDF for full document]